Product Description
Etrolizumab is a next-generation anti-integrin with dual action that targets two pathways of inflammation in the gut. A robust phase 3 clinical program in ulcerative colitis (UC) and Crohn's disease is ongoing and will evaluate the efficacy and safety of etrolizumab in well-defined patient populations in rigorous trials that include direct head-to-head comparisons against approved anti-tumor necrosis factor alpha agents (anti-TNF). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32445184/)
Mechanisms of Action: ITGA4-B7 Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Colitis, Ulcerative
Phase 1: Crohn Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Lantana | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2024-01-23 |
|
| 2017-003649-10 | P1 |
Active, not recruiting |
Crohn Disease|Colitis, Ulcerative |
2023-03-08 |